# Avalyn Pharma Inc.: Phase 2 study closed enrollment, 398 enrolled (Pulmonary Fibrosis, Progressive Pulmonary Fibrosis)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | Avalyn Pharma Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis |
| NCT ID | NCT06329401 |
| Phase | Phase 2 |
| Status | active not recruiting |
| Conditions | Pulmonary Fibrosis; Progressive Pulmonary Fibrosis; Pulmonary Fibrosis Secondary to Systemic Sclerosis; Pulmonary Fibrosis, Interstitial Lung Disease; Interstitial Lung Disease; Interstitial Lung Disease Due to Connective Tissue Disease (Disorder) |
| Intervention types | drug, other |
| Target enrollment | 398 |
| Site countries | United States, Argentina, Australia, Belgium, Canada, France, Germany, Italy, Netherlands, New Zealand, Poland, Spain |
| Posted | 2024-03-25 |
| Planned start | 2024-04-03 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-16 |
| Last update posted | 2026-10-16 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 2: multi-site, larger budget.
- 398 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06329401). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.